HRP20010741A2 - Use of osanetant in the production of medicaments used to treat mood disorders - Google Patents
Use of osanetant in the production of medicaments used to treat mood disorders Download PDFInfo
- Publication number
- HRP20010741A2 HRP20010741A2 HR20010741A HRP20010741A HRP20010741A2 HR P20010741 A2 HRP20010741 A2 HR P20010741A2 HR 20010741 A HR20010741 A HR 20010741A HR P20010741 A HRP20010741 A HR P20010741A HR P20010741 A2 HRP20010741 A2 HR P20010741A2
- Authority
- HR
- Croatia
- Prior art keywords
- osanetant
- treatment
- intended
- use according
- disorders
- Prior art date
Links
- DZOJBGLFWINFBF-UMSFTDKQSA-N osanetant Chemical compound C([C@](C1)(CCCN2CCC(CC2)(N(C(C)=O)C)C=2C=CC=CC=2)C=2C=C(Cl)C(Cl)=CC=2)CCN1C(=O)C1=CC=CC=C1 DZOJBGLFWINFBF-UMSFTDKQSA-N 0.000 title claims description 11
- 229950009875 osanetant Drugs 0.000 title claims description 11
- 208000019022 Mood disease Diseases 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 208000020401 Depressive disease Diseases 0.000 claims description 12
- 150000003839 salts Chemical class 0.000 claims description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 5
- 230000003542 behavioural effect Effects 0.000 claims description 4
- 208000019901 Anxiety disease Diseases 0.000 claims description 2
- 208000020925 Bipolar disease Diseases 0.000 claims description 2
- 230000036506 anxiety Effects 0.000 claims description 2
- 208000024732 dysthymic disease Diseases 0.000 claims description 2
- 229940127554 medical product Drugs 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 239000002775 capsule Substances 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 238000001035 drying Methods 0.000 description 2
- 239000002050 international nonproprietary name Substances 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 238000005550 wet granulation Methods 0.000 description 2
- 101001125071 Homo sapiens Neuromedin-K receptor Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229940123685 Monoamine oxidase inhibitor Drugs 0.000 description 1
- 229940123445 Tricyclic antidepressant Drugs 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000003291 dopaminomimetic effect Effects 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 229910003002 lithium salt Inorganic materials 0.000 description 1
- 159000000002 lithium salts Chemical class 0.000 description 1
- 208000024714 major depressive disease Diseases 0.000 description 1
- 239000002899 monoamine oxidase inhibitor Substances 0.000 description 1
- 101150006061 neur gene Proteins 0.000 description 1
- 230000002474 noradrenergic effect Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 125000004483 piperidin-3-yl group Chemical group N1CC(CCC1)* 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 229940126570 serotonin reuptake inhibitor Drugs 0.000 description 1
- 239000003772 serotonin uptake inhibitor Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 239000003029 tricyclic antidepressant agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Hydrogenated Pyridines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9904699A FR2792199B3 (fr) | 1999-04-13 | 1999-04-13 | Utilisation de l'osanetant pour la preparation de medicaments utiles dans le traitement des troubles de l'humeur |
| PCT/FR2000/000924 WO2000061125A2 (fr) | 1999-04-13 | 2000-04-11 | L'osanetant dans le traitement des troubles de l'humeur |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20010741A2 true HRP20010741A2 (en) | 2002-10-31 |
Family
ID=9544412
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20010741A HRP20010741A2 (en) | 1999-04-13 | 2001-10-12 | Use of osanetant in the production of medicaments used to treat mood disorders |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US6420388B1 (hu) |
| EP (1) | EP1175215A2 (hu) |
| JP (1) | JP2002541190A (hu) |
| KR (1) | KR20010105418A (hu) |
| CN (1) | CN1354662A (hu) |
| AR (1) | AR023452A1 (hu) |
| AU (1) | AU3971600A (hu) |
| BR (1) | BR0009704A (hu) |
| CA (1) | CA2369638A1 (hu) |
| CZ (1) | CZ20013645A3 (hu) |
| EE (1) | EE200100527A (hu) |
| FR (1) | FR2792199B3 (hu) |
| HR (1) | HRP20010741A2 (hu) |
| HU (1) | HUP0200655A3 (hu) |
| ID (1) | ID30458A (hu) |
| IS (1) | IS6098A (hu) |
| MX (1) | MXPA01010340A (hu) |
| NO (1) | NO20014953L (hu) |
| PE (1) | PE20010032A1 (hu) |
| PL (1) | PL351554A1 (hu) |
| SK (1) | SK14552001A3 (hu) |
| TR (1) | TR200102930T2 (hu) |
| WO (1) | WO2000061125A2 (hu) |
| ZA (1) | ZA200108289B (hu) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE367811T1 (de) * | 2000-06-12 | 2007-08-15 | Univ Rochester | Methode zur behandlung von hitzewallungen, durch verwendung eines tachikinin-rezeptor antagonisten |
| TWI329649B (en) * | 2003-12-22 | 2010-09-01 | Glaxo Group Ltd | Immunoglobulins |
| US20070244152A1 (en) * | 2004-03-25 | 2007-10-18 | Lowy Martin T | Use of an Nk3 Antagonist for the Treatment of Bipolar Disorders |
| WO2006098488A1 (ja) | 2005-03-15 | 2006-09-21 | Sumitomo Chemical Company, Limited | 気分障害による疾患症状を改善させる方法 |
| JP2006320201A (ja) * | 2005-05-17 | 2006-11-30 | Sumitomo Chemical Co Ltd | 気分障害又は関連障害による疾患症状を改善させる方法 |
| GB0525662D0 (en) | 2005-12-16 | 2006-01-25 | Glaxo Group Ltd | Immunoglobulins |
| WO2015200594A2 (en) * | 2014-06-25 | 2015-12-30 | Emory University | Methods of managing conditioned fear with neurokinin receptor antagonists |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2719311B1 (fr) | 1994-03-18 | 1998-06-26 | Sanofi Sa | Composés antagonistes sélectifs du récepteur NK3 humain et leur utilisation comme médicaments et outils de diagnostic. |
| FR2729954B1 (fr) * | 1995-01-30 | 1997-08-01 | Sanofi Sa | Composes heterocycliques substitues, procede pour leur preparation et compositions pharmaceutiques les contenant |
| FR2738819B1 (fr) | 1995-09-14 | 1997-12-05 | Sanofi Sa | Nouveaux composes antagonistes selectifs du recepteur nk3 humain, procede pour leur obtention et compositions pharmaceutiques les contenant |
| AU4176997A (en) | 1996-09-16 | 1998-04-02 | Warner-Lambert Company | 3-alkyl-3-phenyl-piperidines |
-
1999
- 1999-04-13 FR FR9904699A patent/FR2792199B3/fr not_active Expired - Fee Related
-
2000
- 2000-04-11 JP JP2000610458A patent/JP2002541190A/ja not_active Withdrawn
- 2000-04-11 EP EP00918941A patent/EP1175215A2/fr not_active Withdrawn
- 2000-04-11 ID IDW00200102144A patent/ID30458A/id unknown
- 2000-04-11 TR TR2001/02930T patent/TR200102930T2/xx unknown
- 2000-04-11 MX MXPA01010340A patent/MXPA01010340A/es not_active Application Discontinuation
- 2000-04-11 CZ CZ20013645A patent/CZ20013645A3/cs unknown
- 2000-04-11 EE EEP200100527A patent/EE200100527A/xx unknown
- 2000-04-11 SK SK1455-2001A patent/SK14552001A3/sk unknown
- 2000-04-11 AU AU39716/00A patent/AU3971600A/en not_active Abandoned
- 2000-04-11 BR BR0009704-7A patent/BR0009704A/pt not_active Application Discontinuation
- 2000-04-11 US US09/958,266 patent/US6420388B1/en not_active Expired - Fee Related
- 2000-04-11 PL PL00351554A patent/PL351554A1/xx not_active Application Discontinuation
- 2000-04-11 KR KR1020017012990A patent/KR20010105418A/ko not_active Application Discontinuation
- 2000-04-11 WO PCT/FR2000/000924 patent/WO2000061125A2/fr not_active Application Discontinuation
- 2000-04-11 CN CN00806091A patent/CN1354662A/zh active Pending
- 2000-04-11 CA CA002369638A patent/CA2369638A1/en not_active Abandoned
- 2000-04-11 HU HU0200655A patent/HUP0200655A3/hu unknown
- 2000-04-12 AR ARP000101670A patent/AR023452A1/es unknown
- 2000-04-13 PE PE2000000343A patent/PE20010032A1/es not_active Application Discontinuation
-
2001
- 2001-09-28 IS IS6098A patent/IS6098A/is unknown
- 2001-10-09 ZA ZA200108289A patent/ZA200108289B/xx unknown
- 2001-10-11 NO NO20014953A patent/NO20014953L/no not_active Application Discontinuation
- 2001-10-12 HR HR20010741A patent/HRP20010741A2/hr not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| AU3971600A (en) | 2000-11-14 |
| CN1354662A (zh) | 2002-06-19 |
| EE200100527A (et) | 2002-12-16 |
| FR2792199B3 (fr) | 2001-05-18 |
| WO2000061125A2 (fr) | 2000-10-19 |
| KR20010105418A (ko) | 2001-11-28 |
| CA2369638A1 (en) | 2000-10-19 |
| HUP0200655A3 (en) | 2002-11-28 |
| JP2002541190A (ja) | 2002-12-03 |
| HUP0200655A2 (hu) | 2002-07-29 |
| NO20014953L (no) | 2001-12-11 |
| CZ20013645A3 (cs) | 2002-01-16 |
| TR200102930T2 (tr) | 2002-04-22 |
| EP1175215A2 (fr) | 2002-01-30 |
| MXPA01010340A (es) | 2002-05-06 |
| PL351554A1 (en) | 2003-05-05 |
| BR0009704A (pt) | 2002-01-08 |
| FR2792199A1 (fr) | 2000-10-20 |
| ZA200108289B (en) | 2002-12-24 |
| AR023452A1 (es) | 2002-09-04 |
| IS6098A (is) | 2001-09-28 |
| ID30458A (id) | 2001-12-06 |
| NO20014953D0 (no) | 2001-10-11 |
| US6420388B1 (en) | 2002-07-16 |
| WO2000061125A3 (fr) | 2001-04-19 |
| SK14552001A3 (sk) | 2002-02-05 |
| PE20010032A1 (es) | 2001-04-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6444665B1 (en) | Method for treating pain | |
| HU225534B1 (en) | Pharmaceutical compositions comprising mirtazapine and one or more selective serotonin reuptake inhibitors | |
| EP1154795B1 (en) | Means for treating and diagnosing restless legs syndrome | |
| JPS59193821A (ja) | 抗不安薬としてのフルオキセチンの使用法 | |
| AU1217697A (en) | Method of treating and diagnosing sleep disordered breathing and means for carrying out the method | |
| KR20010032009A (ko) | 수면성 무호흡의 치료에 미타자핀을 사용하는 방법 | |
| ZA200600159B (en) | Novel solid pharmaceutical composition comprising amisulpride | |
| HRP20010741A2 (en) | Use of osanetant in the production of medicaments used to treat mood disorders | |
| PL196479B1 (pl) | Zastosowanie saredutantu i jego farmaceutycznie dopuszczalnych soli do wytwarzania leków | |
| RU2261098C2 (ru) | Перорально распадающаяся композиция, содержащая миртазапин | |
| US4719212A (en) | Therapeutic agent for memory disturbance | |
| JP5386477B2 (ja) | 脊髄損傷を治療するための４−シクロプロピルメトキシ−ｎ−（３，５−ジクロロ−１−オキシドピリジン−４−イル）−５−（メトキシ）ピリジン−２−カルボキサミドの使用 | |
| WO1998024411A2 (en) | Method for oral administration of buspirone | |
| EA010868B1 (ru) | Применение производных бицикло[2.2.1]гептана для приготовления нейропротекторных фармацевтических композиций | |
| WO2007007133A2 (en) | Composition for treatment of psychosis | |
| TWI417090B (zh) | 黃酮類化合物於治療伴有感覺運動門控缺損的精神異常疾病的用途 | |
| JP5386476B2 (ja) | 頭蓋外傷の治療のための４−シクロプロピルメトキシ−ｎ−（３，５−ジクロロ−１−オキシド−４−ピリジン−４−イル）−５−（メトキシ）ピリジン−２−カルボキサミドの使用 | |
| JP2010524906A (ja) | パーキンソン病に伴う運動不全の治療のための４−シクロプロピルメトキシ−ｎ−（３，５−ジクロロ−１−オキシドピリジン−４−イル）−５−（メトキシ）ピリジン−２−カルボキサミドの使用 | |
| EA003584B1 (ru) | Способ стимуляции отказа от курения или его снижения или предупреждения возобновления курения и применение пароксетина или его фармацевтически приемлемых солей или сольватов для получения лекарственного средства | |
| WO2002056869A2 (en) | Method for treating sexual disorders | |
| CN116920101A (zh) | 一种用于重度抑郁症治疗的新的药物组合 | |
| KR20220110259A (ko) | 통증 질환에 사용하기 위한 미르타자핀 및 티자니딘 배합물 | |
| KR20010099647A (ko) | 신규 조성물 | |
| WO2002043727A1 (en) | Treatment of psychiatric disorders with trimethyl-bicyclo[2.2.1]heptane derivatives | |
| EP1353656A2 (en) | Method for treating stress or tension |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| ODRP | Renewal fee for the maintenance of a patent |
Payment date: 20020411 Year of fee payment: 3 |
|
| A1OB | Publication of a patent application | ||
| OBST | Application withdrawn |